Back to Search Start Over

Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis

Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis

Authors :
Lisa Butler
Amy M. DeLozier
Elizabeth D. Bacci
Wendy Begolka
Evangeline Pierce
Julia Correll
Maria Jose Rueda
Anne Rentz
Source :
Journal of Drugs in Dermatology. 20:1222-1230
Publication Year :
2021
Publisher :
SanovaWorks, 2021.

Abstract

Background Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease causing a variety of dermatologic signs and symptoms, affecting patientrs quality of life. While treatment options are available, they are of variable effectiveness. This study sought to characterize patient-reported AD signs and symptoms, flare, and associated bother, by disease severity and control. Methods Adults diagnosed with AD were recruited through the National Eczema Association (NEA) and clinical sites and completed a web-based survey including the Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD), Recap of Atopic Eczema (RECAP), and Skin Pain numeric rating scale (NRS), as well as questions on previous/current clinical presentation, flare frequency and severity, past/ present AD treatment, and sociodemographic characteristics. Results A total of 186 participants completed the survey (mean age 39.7 years, 80% female). The most frequently reported current AD signs and symptoms included dryness, itch, redness, roughness, and flaking skin, and the most bothersome were itch, dryness, and redness (63%). The majority of participants (84%) were either currently experiencing a flare or had experienced one within the past month. The most common signs and symptoms that grew worse during the most recent flare were itch and redness across all disease severity groups. Participants most often experienced one to three flares in the last three months. Flare frequency, duration, and average severity increased with greater disease severity and lack of disease control. Conclusions The results of this study demonstrate the diverse and considerable symptomatic burden experienced by people with AD, even while being treated for AD. J Drugs Dermatol. 2021;20(11):1222-1230. doi:10.36849/JDD.6329.

Details

ISSN :
15459616
Volume :
20
Database :
OpenAIRE
Journal :
Journal of Drugs in Dermatology
Accession number :
edsair.doi.dedup.....983a2da736a647ee63b1f18d7ac8d9bf
Full Text :
https://doi.org/10.36849/jdd.6329